Navigation Links
'Multi-target' immune therapy improves outcomes of severe lupus nephritis
Date:7/1/2008

A new treatment using a combination of drugs targeting different parts of the immune system improves the recovery rate for patients with severe lupus involving the kidneys, according to a report in the October Journal of the American Society of Nephrology (JASN).

"In our study, multi-target therapy is shown to be superior to traditional therapy for inducing complete remission of class V+IV lupus nephritis, with few side effects," comments Dr. Lei-Shi Li of the Research Institute of Nephrology of Jinling Hospital, Nanjing University School of Medicine in Nanjing,China.

The study included 40 patients with severe lupus nephritis. Lupus nephritis is inflammation of the kidneys occurring in patients with the immune system disease systemic lupus erythematosus (SLE). All patients had "class V+IV" disease, meaning widespread inflammation and decreasing function of the kidneys. "This is a severe form of lupus nephritis that is traditionally treated with a single immunosuppressant drug, but the efficacy is very poor," says Dr. Li. "We considered that, since the impact of severe SLE on the kidney involves various parts of the immune system, it is necessary to treat the different immune targets with a combination of immunosuppressant drugs."

One group of patients received this "multi-target" therapy, consisting of the immunosuppressant drugs tacrolimus and mycophenolate mofetilcommonly used as anti-rejection drugs in transplant patientsplus a steroid. The other group received standard treatment with a single immunosuppressant drug (cyclophosphamide).

The complete remission rate, with recovery of normal kidney function, was about four times higher among patients receiving the three-drug combination. "For patients receiving multi-target therapy, the complete remission rate reached 65 percent at nine months, versus only 15 percent under traditional therapy," says Dr. Li.

Some patients in both groups had partial remission, with some return of kidney function. Overall, 95 percent of patients in the multi-target therapy group had partial or complete remission, compared to 55 percent with single-drug therapy. The rate of most adverse effects was also lower with multi-target therapy.

Systemic lupus erythematosus is an autoimmune disorder, in which the immune system attacks healthy organs and tissues. By reducing immune system activity, treatment with immunosuppressant drugs has improved most outcomes for patients with SLE. However, class V+IV lupus nephritis continues to be a major problemit has a poor response to traditional treatments and can lead to permanent kidney damage. "The prognosis is very poor, so it is important for us to develop a new regimen for the treatment of this type of lupus nephritis," says Dr. Li.

Using a combination of drugs that affect different immune targets, multi-target therapy improves the chances of remission for patients with severe lupus nephritis. "The therapeutic effect of our multi-target therapy is apparently superior to traditional therapy for inducing complete remission of Class V+IV lupus nephritis, and also bears good tolerance under relatively lower dosages," Dr. Li adds.

The authors stress that their study is only preliminary. The study includes a small group of patients from a single hospital, with a relatively short follow-up time. Larger randomized trials with longer follow-up are required.


'/>"/>

Contact: Shari Leventhal
sleventhal@asn-online.org
202-416-0658
American Society of Nephrology
Source:Eurekalert

Related medicine news :

1. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. Immune deficiency linked to a type of eye cancer
4. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
5. Melanoma drug revs immune cells but cancer cells ignore it
6. Study identifies key player in the bodys immune response to chronic stress
7. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
8. UVA researchers find important clue to immune infertility
9. M.D. Anderson-led team reports possible key to autoimmune disease
10. Their immune cells, fighting your cancer
11. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... August 18, ... & Hearing,” advocating for active, healthy lifestyles and highlighting the importance of proactive ... with hearing impairments and shares the latest innovations in hearing aid technology. ...
(Date:8/18/2017)... ... , ... The Dawn Johnson Insurance Group, a Missouri-based insurance and financial planning ... support for efforts to educate the local population on cancer realities while attracting donations ... , Each day in America, roughly 4,600 new cases of cancer are diagnosed ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, ... communities in east Texas, is launching a regional charity effort to provide publicity ... 1991, the Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... firm that serves residential and commercial clients in the greater Houston region, is ... community support for the fight against cancer. , Founded by Tony and Amber ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... practitioners specializing in bioidentical hormone replacement therapy and integrative medicine, has become a ... conditions of aging, such as menopause, andropause, thyroid disorder and adrenal insufficiencies. ...
Breaking Medicine News(10 mins):
(Date:8/4/2017)... 2017 The search for test results that ... consult has long been the goal of healthcare providers ... of the largest meeting of lab professionals and IVD ... research firm Kalorama Information.  The firm said scores of ... related supplies and software were at the American Association ...
(Date:8/2/2017)... 2, 2017  Life Flight Network and PeaceHealth Oregon Network ... patient care and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, ... and Life Flight Network work collaboratively to move patients who ... when a time sensitive emergency exists. ...
(Date:7/31/2017)... Surgical, developer of ground breaking surgical navigation technologies, announced today ... support its strategic sales plan in Maryland ... Surgical has entered into an exclusive sales representative agreement with ... those markets. ... Spartan Medical Purchases 7D Surgical Technology ...
Breaking Medicine Technology: